Increased TGF-β-3 expression may contribute to this resistance by promoting immunosuppression and angiogenesis in the tumor microenvironment, suggesting that targeted inhibition of TGF-β-3 could enhance the effectiveness of existing therapies. The gene discussed is TGFB3; the disease is neoplasm.